CD19 and acute lymphoblastic leukemia: treated 43 pediatric and adult RR-ALL patients with CD19 CAR-T cell therapy and demonstrated that the ongoing persistence of functional CD19 CAR-T cells or BCA for more than 6 months was a major determinant of durable remission, which was positively correlated with CD19 antigen burden at the time of infusion (46).